Navigation Links
BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
Date:5/3/2011

NOVATO, Calif., May 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 10, 2011 at 2:20 p.m. PT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin Announces First Quarter 2011 Financial Results
2. BioMarin to Present at the Deutsche Bank Healthcare Conference
3. BioMarin to Present at the Barclays Global Healthcare Conference
4. BioMarin to Present at the Cowen Health Care Conference
5. BioMarin to Present at the Citi Global Healthcare Conference
6. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
7. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
8. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
10. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
11. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014   Wellcentive , ... (PHM) for healthcare organizations, announced today being named ... 2014 Intel Innovation Award .  Sponsored by Intel, ... in its fourth year, recognizes companies developing leading-edge ... healthcare delivery processes. Wellcentive,s ...
(Date:11/21/2014)... Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its offering of $80,000,000 aggregate principal amount of 5.25% ... a private offering within the United States ... institutional buyers pursuant to Rule 144A under the Securities ... has also granted the initial purchasers an option to ...
(Date:11/18/2014)... WALTHAM, Mass. , Nov. 18, 2014 ... one of the leading medical device and services providers ... Motion,s exclusive partner for Respiratory Motion,s innovative respiratory depression ... Respiratory Motion and IMI are working together to connect ... IMI has a long history of bringing innovative medical ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... Pharmaceuticals Inc . (Nasdaq: CPIX) is pleased to ... Directors. A healthcare veteran with more than 30 ... President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. ... $2 billion behavioral healthcare system before the company,s sale to ...
... Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... China, announced today its preliminary unaudited sales range for the ... conference call to discuss these preliminary sales will be held ... (January 6, 2011 at 9:00 pm China Standard Time). The ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 3
(Date:11/21/2014)... November 21, 2014 Recently, TideStore.com, a ... accessories, has announced its special offer TideStore Thanksgiving ... items at TideStore.com are now provided with big discounts. ... 25. People can enjoy an extra 10% discount with ... their email addresses and have opportunities to win free ...
(Date:11/21/2014)... 2014 According to a National Highway ... 11th, 2014, the inflating system found in certain airbags ... inflates. The force of inflation may cause the metal ... shards may pierce the airbag’s fabric and potentially cause ... According to a Bloomberg Business Week article ...
(Date:11/21/2014)... By Dennis Thompson ... -- Overweight or obese women who get pregnant are much ... disease as an adult, new research suggests. But it ... in that trend, the researchers added. "Mothers who are ... study author Dr. Michael Mendelson. He is a research fellow ...
(Date:11/21/2014)... Reinberg HealthDay Reporter THURSDAY, ... to excess or binge drink are not alcoholics, a new ... those who drink too much aren,t dependent on alcohol. But ... U.S. Centers for Disease Control and Prevention. , , "A lot ... are alcoholics," said study co-author Dr. Robert Brewer, the leader ...
(Date:11/18/2014)... 18, 2014 Examination Management Services, ... risk management and investigative services, has launched a ... Model to enhance its paramedical exam service to ... Through use of EMSI’s 5 Star Examiner Performance ... their paramedical exams are conducted by examiners whose ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Sales from TideStore.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 2Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 3Health News:EMSI Launches Proprietary 5 Star Examiner Performance Model to Enhance Paramedical Exam Service 2
... in training have a 17 percent less chance of ... surgery at non-teaching hospitals, according to results of a ... the Annals of Thoracic Surgery. , Theres a ... because of training issues, and concerns are frequently voiced ...
... Senate Letter asks Lawmakers to Reject Funding Reductions ... Reform Much More,Difficult to Achieve, Letter Draws ... March 4 The Council for Quality,Respiratory Care ... home oxygen,therapy providers and manufacturers who provide care ...
... and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals,today ... healthy subjects in,a Phase I study of AFN-1252, ... class of fatty acid biosyntheis inhibitors. The study ... of a single,escalating oral dose. Affinium believes that ...
... Data from one of the first genome-wide association studies ... in part by The Michael J. Fox Foundation for ... researchers through the National Human Genome Research Institute (NHGRI) ... of the National Institutes of Health (NIH). NHGRI hopes ...
... experience a significant improvement in their quality of ... new research published in the March 2008 issue ... The German study evaluated the quality of life ... Cochlear Implant Questionnaire (NCIQ), a self-administered assessment that ...
... the users risk of head and neck cancer, according to ... Otolaryngology Head and Neck Surgery. , The small sample ... found that among 75 cases of head and neck cancer, ... neck cancer in marijuana users was the same (1.0) as ...
Cached Medicine News:Health News:Risk of surgery for lung cancer lower at teaching hospitals 2Health News:Bi-Partisan Members of United States Senate Formally Raise Concerns About Proposed Cuts to Medicare's Home Oxygen Benefit 2Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 2Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 3Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 4Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 5
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... people are diagnosed with varicose veins every ... never seek treament and are apprehensive of ... them an effective alternative to conventional therapies., ... hook phlebectomy), is considered a laborious procedure ...
Inquire...
...
Medicine Products: